BR112022006381A2 - Pró-fármacos de inibidores de mieloperoxidase - Google Patents
Pró-fármacos de inibidores de mieloperoxidaseInfo
- Publication number
- BR112022006381A2 BR112022006381A2 BR112022006381A BR112022006381A BR112022006381A2 BR 112022006381 A2 BR112022006381 A2 BR 112022006381A2 BR 112022006381 A BR112022006381 A BR 112022006381A BR 112022006381 A BR112022006381 A BR 112022006381A BR 112022006381 A2 BR112022006381 A2 BR 112022006381A2
- Authority
- BR
- Brazil
- Prior art keywords
- prodrugs
- myeloperoxidase
- myeloperoxidase inhibitor
- mpo
- inhibitor prodrugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913417P | 2019-10-10 | 2019-10-10 | |
| PCT/US2020/054896 WO2021072140A1 (en) | 2019-10-10 | 2020-10-09 | Prodrugs of myeloperoxidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022006381A2 true BR112022006381A2 (pt) | 2022-06-28 |
Family
ID=75438074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022006381A BR112022006381A2 (pt) | 2019-10-10 | 2020-10-09 | Pró-fármacos de inibidores de mieloperoxidase |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240067651A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4041735A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022552834A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220080133A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114945573A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020363903A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022006381A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3157260A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL291891A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022004203A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021072140A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010902A (es) * | 2020-03-05 | 2022-10-07 | Biohaven Therapeutics Ltd | Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa. |
| CN115403584B (zh) * | 2021-05-26 | 2024-04-02 | 长春金赛药业有限责任公司 | 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990012797A1 (en) * | 1989-04-19 | 1990-11-01 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Sulfer-containing xanthine derivatives as adenosin antagonists |
| MY140748A (en) * | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| NZ544187A (en) * | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
| WO2007069924A1 (en) * | 2005-12-15 | 2007-06-21 | Industrial Research Limited | Deazapurine analogs of 4'-aza-l-nucleosides |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
| NZ604423A (en) * | 2010-06-24 | 2015-01-30 | Alkermes Pharma Ireland Ltd | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC | ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体 |
| DK3265448T3 (da) * | 2015-03-03 | 2022-03-28 | Biohaven Therapeutics Ltd | Riluzol-prodrugs og anvendelse deraf |
| SG11202000086PA (en) * | 2017-07-17 | 2020-02-27 | Astrazeneca Ab | Mpo inhibitors for use in medicine |
-
2020
- 2020-10-09 KR KR1020227015015A patent/KR20220080133A/ko not_active Withdrawn
- 2020-10-09 MX MX2022004203A patent/MX2022004203A/es unknown
- 2020-10-09 AU AU2020363903A patent/AU2020363903A1/en not_active Abandoned
- 2020-10-09 JP JP2022521147A patent/JP2022552834A/ja active Pending
- 2020-10-09 BR BR112022006381A patent/BR112022006381A2/pt not_active IP Right Cessation
- 2020-10-09 IL IL291891A patent/IL291891A/en unknown
- 2020-10-09 US US17/766,539 patent/US20240067651A1/en not_active Abandoned
- 2020-10-09 EP EP20874337.7A patent/EP4041735A4/en not_active Withdrawn
- 2020-10-09 WO PCT/US2020/054896 patent/WO2021072140A1/en not_active Ceased
- 2020-10-09 CN CN202080070666.8A patent/CN114945573A/zh active Pending
- 2020-10-09 CA CA3157260A patent/CA3157260A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022552834A (ja) | 2022-12-20 |
| AU2020363903A1 (en) | 2022-03-24 |
| MX2022004203A (es) | 2022-07-04 |
| CA3157260A1 (en) | 2021-04-15 |
| EP4041735A4 (en) | 2023-11-22 |
| IL291891A (en) | 2022-06-01 |
| KR20220080133A (ko) | 2022-06-14 |
| CN114945573A (zh) | 2022-08-26 |
| WO2021072140A1 (en) | 2021-04-15 |
| US20240067651A1 (en) | 2024-02-29 |
| EP4041735A1 (en) | 2022-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020014315A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington. | |
| WO2019191229A8 (en) | Compounds for treating huntington's disease | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| BR112022007867A2 (pt) | Degradadores de pequena molécula de helios e métodos de uso | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| BR112022007947A2 (pt) | Uso de modulador de splicing para tratamento que retarda a progressão da doença de huntington | |
| BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
| MA40814A1 (fr) | Compositions pharmaceutiques pour thérapie combinée | |
| MY155633A (en) | Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy | |
| BR112015031903A8 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto | |
| CO2022009787A2 (es) | Agentes de arni del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72), composiciones y métodos de uso de los mismos | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| BR112019001923A2 (pt) | moduladores de nmda de espiro-lactama e métodos de sua utilização | |
| MX2021006347A (es) | Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2. | |
| BRPI0409498A (pt) | uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto | |
| BR112021018254A2 (pt) | Derivados de nicorandil | |
| BRPI0919057A2 (pt) | compostos de indazol ou derivados, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento ou profilaxia de enfermidades que são afetadas por moduladores de fxr, e uso dos compostos | |
| BR112022020147A2 (pt) | Compostos para tratar a doença de huntington | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
| BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
| BR112022009086A2 (pt) | Inibidores alostéricos de egfr e métodos de uso dos mesmos | |
| MX2024009773A (es) | Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso. | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| BR112023017713A2 (pt) | Composições compreendendo profármacos cliváveis por enzima e nafamostato de liberação controlada e métodos de uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2848 DE 05-08-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |